# Biotech M&A

Eli Lilly Bets $7 Billion on the ‘Holy Grail’ of Cancer Therapy to Diversify Beyond Weight Loss

Eli Lilly is acquiring Kelonia Therapeutics for up to $7 billion to gain access to its revolutionary in-vivo CAR-T technology. This strategic move aims to diversify Lilly's portfolio beyond its successful weight-loss business and establish a leading position in the high-growth oncology market.